{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:09:13Z","timestamp":1759741753784},"reference-count":150,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Intramural Research Program of the NIH"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Center for Cancer Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.vaccine.2011.06.088","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T20:48:33Z","timestamp":1310158113000},"page":"6485-6497","source":"Crossref","is-referenced-by-count":17,"title":["Immunotherapy in prostate cancer: Emerging strategies against a formidable foe"],"prefix":"10.1016","volume":"29","author":[{"given":"Marijo","family":"Bilusic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Heery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.06.088_bib0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0010","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","article-title":"Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results","volume":"172","author":"Roehl","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60885-8","article-title":"Proteasomes and antigen processing","volume":"64","author":"Tanaka","year":"1997","journal-title":"Adv Immunol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.immuni.2007.04.003","article-title":"The final touches make perfect the peptide-MHC class I repertoire","volume":"26","author":"Hammer","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0025","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0030","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.eururo.2007.08.047","article-title":"PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes\u2014results from the SEARCH database","volume":"53","author":"Freedland","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/13543780902997928","article-title":"Prostvac-V.F: a vector-based vaccine targeting PSA in prostate cancer","volume":"18","author":"Madan","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0040","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1517\/14712590903446921","article-title":"A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer","volume":"9","author":"Fishman","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0045","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/CJI.0b013e3181dda23e","article-title":"DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer","volume":"33","author":"Becker","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0050","doi-asserted-by":"crossref","first-page":"24561","DOI":"10.1074\/jbc.M402492200","article-title":"The T cell receptor gamma chain alternate reading frame protein (TARP), a prostate-specific protein localized in mitochondria","volume":"279","author":"Maeda","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0055","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/eji.200737524","article-title":"Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies","volume":"38","author":"Epel","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00262-009-0723-6","article-title":"New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy","volume":"59","author":"Cereda","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2008.08.034","article-title":"Prostate stem cell antigen: a prospective therapeutic and diagnostic target","volume":"277","author":"Raff","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0070","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/0008-5472.CAN-06-2996","article-title":"In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer","volume":"67","author":"Garcia-Hernandez","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0075","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ijc.21158","article-title":"Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action","volume":"117","author":"Sabbisetti","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0080","article-title":"Identification of AKAP-4 as a new cancer\/testis antigen for detection and immunotherapy of prostate cancer","author":"Chiriva-Internati","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1600-065X.1995.tb00077.x","article-title":"MUC-1 epithelial tumor mucin-based immunity and cancer vaccines","volume":"145","author":"Finn","year":"1995","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10585-005-5376-z","article-title":"MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer","volume":"22","author":"Cozzi","year":"2005","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0095","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1158\/1078-0432.CCR-07-0879","article-title":"Universal and stemness-related tumor antigens: potential use in cancer immunotherapy","volume":"13","author":"Parmiani","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0100","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/1097-0215(20000901)87:5<680::AID-IJC10>3.0.CO;2-P","article-title":"Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A\/J mice","volume":"87","author":"Fu","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0110","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1158\/1078-0432.CCR-07-1654","article-title":"Transforming growth factor-beta and the immune response to malignant disease","volume":"13","author":"Teicher","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/156800907780006896","article-title":"Indoleamine 2,3-dioxygenase in immune suppression and cancer","volume":"7","author":"Muller","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0120","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00262-009-0782-8","article-title":"Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer","volume":"59","author":"Gulley","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0125","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","article-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer","volume":"21","author":"Halabi","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/(SICI)1097-0045(19980701)36:2<129::AID-PROS8>3.0.CO;2-D","article-title":"Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide","volume":"36","author":"Peshwa","year":"1998","journal-title":"Prostate"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0135","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1200\/JCO.2000.18.23.3894","article-title":"Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells","volume":"18","author":"Small","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0140","first-page":"2175","article-title":"Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer","volume":"6","author":"Burch","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/pros.20040","article-title":"Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial","volume":"60","author":"Burch","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0150","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0155","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0160","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0165","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-10-3223","article-title":"Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer","author":"Beer","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0170","unstructured":"Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer (NeoACT). [June 2011]; Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00715104."},{"key":"10.1016\/j.vaccine.2011.06.088_bib0175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/j.seminoncol.2005.09.006","article-title":"Pox viral vaccine approaches","volume":"32","author":"Arlen","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0180","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0185","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2004.08.083","article-title":"Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group","volume":"22","author":"Kaufman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0190","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1128\/JVI.76.7.3329-3337.2002","article-title":"Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope","volume":"76","author":"Harrington","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0195","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.juro.2007.05.117","article-title":"Clinical safety of a viral vector-based prostate cancer vaccine strategy","volume":"178","author":"Arlen","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0200","unstructured":"DiPaola R, Chen Y, Bubley G, Hahn N, Stein M, Schlom J, et al. A phase II study of PROSTVAC-V (vaccinia)\/TRICOM and PROSTVAC-F (fowlpox)\/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: results of ECOG 9802 [abstract]. ASCO Genitourinary Cancers Symposium 2009:108."},{"key":"10.1016\/j.vaccine.2011.06.088_bib0205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/pros.10130","article-title":"Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer","volume":"53","author":"Gulley","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0210","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1158\/1078-0432.CCR-04-2062","article-title":"Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer","volume":"11","author":"Gulley","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0215","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.ju.0000165159.33772.5b","article-title":"Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer","volume":"174","author":"Arlen","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0220","first-page":"1632","article-title":"A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer","volume":"6","author":"Eder","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0225","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0090-4295(98)00539-1","article-title":"Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer","volume":"53","author":"Sanda","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0230","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0952-7915(97)80053-2","article-title":"Serological identification of human tumor antigens","volume":"9","author":"Sahin","year":"1997","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0240","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","article-title":"Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment","volume":"26","author":"Fong","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0245","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","article-title":"Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies","volume":"110","author":"O\u2019Day","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0250","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0255","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma","author":"Hersh","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0260","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O\u2019Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0265","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0270","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/0008-5472.CAN-08-3529","article-title":"Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF","volume":"69","author":"Fong","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0275","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0280","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0285","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0290","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"15S","key":"10.1016\/j.vaccine.2011.06.088_bib0295","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/jco.2008.26.15_suppl.5004","article-title":"Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract]","volume":"26","author":"Beer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0300","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","article-title":"Ipilimumab: controversies in its development, utility and autoimmune adverse events","volume":"58","author":"Weber","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0305","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0310","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1073\/pnas.95.12.6919","article-title":"Identification of multiple cancer\/testis antigens by allogeneic antibody screening of a melanoma cell line library","volume":"95","author":"Chen","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0315","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.0.CO;2-P","article-title":"Characterization of human colon cancer antigens recognized by autologous antibodies","volume":"76","author":"Scanlan","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0320","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1517\/14712598.7.12.1893","article-title":"GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer","volume":"7","author":"Ward","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0325","unstructured":"Small E, Demkow T, Gerritsen W, Rolland F, Hoskin P, Smith D, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract]. ASCO Genitourinary Cancers Symposium 2009:7."},{"key":"10.1016\/j.vaccine.2011.06.088_bib0330","unstructured":"Higano C, Saad F, Somer B, Curti B, Petrylak D, Drake C, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract]. ASCO Genitourinary Cancers Symposium 2009:LBA150."},{"key":"10.1016\/j.vaccine.2011.06.088_bib0335","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cncr.23669","article-title":"Phase 1\/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer","volume":"113","author":"Higano","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0340","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2307\/2531910","article-title":"Sample sizes based on the log-rank statistic in complex clinical trials","volume":"44","author":"Lakatos","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0345","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc2326","article-title":"DNA vaccines: precision tools for activating effective immunity against cancer","volume":"8","author":"Rice","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0350","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/14760584.6.2.227","article-title":"Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells","volume":"6","author":"Tsen","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0355","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","article-title":"Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer","volume":"27","author":"McNeel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0360","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14712590903321421","article-title":"Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design","volume":"10","author":"Madan","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0365","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1073\/pnas.96.16.9287","article-title":"High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate","volume":"96","author":"Essand","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0370","first-page":"8122","article-title":"T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin","volume":"61","author":"Wolfgang","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0375","first-page":"163","article-title":"MUC1 expression in prostate carcinoma: correlation with grade and stage","volume":"3","author":"Kirschenbaum","year":"1999","journal-title":"Mol Urol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0380","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1200\/JCO.2005.13.011","article-title":"Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer","volume":"23","author":"Butts","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0385","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-5347(06)00494-0","article-title":"A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy","volume":"176","author":"North","year":"2006","journal-title":"J Urol"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2011.06.088_bib0390","doi-asserted-by":"crossref","first-page":"B89","DOI":"10.1016\/j.vaccine.2007.04.091","article-title":"Enhancing efficacy of therapeutic vaccinations by combination with other modalities","volume":"25","author":"Gulley","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0395","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1044-579X(02)00131-1","article-title":"Cell surface death receptor signaling in normal and cancer cells","volume":"13","author":"Ozoren","year":"2003","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0400","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4049\/jimmunol.167.3.1137","article-title":"Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells","volume":"167","author":"Piccirillo","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0405","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.4049\/jimmunol.168.9.4272","article-title":"Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation","volume":"168","author":"Woo","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0410","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","article-title":"Regulatory T cells: key controllers of immunologic self-tolerance","volume":"101","author":"Sakaguchi","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0415","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00205600","article-title":"Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells","volume":"26","author":"Mule","year":"1988","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0420","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/ijc.25177","article-title":"Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine","volume":"127","author":"Farsaci","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0425","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy","volume":"170","author":"Chakraborty","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0430","first-page":"37","article-title":"Combining radiation and immunotherapy for synergistic antitumor therapy","volume":"11","author":"Ferrara","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0435","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1158\/0008-5472.CAN-04-0073","article-title":"External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing","volume":"64","author":"Chakraborty","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0440","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-10-0948","article-title":"A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients","volume":"16","author":"Nesslinger","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0445","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","article-title":"Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement","volume":"14","author":"Garnett","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0450","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-05-2059","article-title":"A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer","volume":"12","author":"Arlen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0455","first-page":"2219","article-title":"Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas","volume":"6","author":"von Mehren","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0460","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0465","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI35180","article-title":"The anticancer immune response: indispensable for therapeutic success?","volume":"118","author":"Zitvogel","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0470","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/0008-5472.CAN-09-3566","article-title":"Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity","volume":"70","author":"Aymeric","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0480","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.2741\/2441","article-title":"Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer","volume":"12","author":"Aragon-Ching","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0485","doi-asserted-by":"crossref","first-page":"14565","DOI":"10.1073\/pnas.251140998","article-title":"T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer","volume":"98","author":"Mercader","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0490","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/01.tp.0000183962.64777.da","article-title":"Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation","volume":"80","author":"Goldberg","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0495","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ccr.2005.01.027","article-title":"Androgen ablation mitigates tolerance to a prostate\/prostate cancer-restricted antigen","volume":"7","author":"Drake","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0500","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.4049\/jimmunol.175.4.2741","article-title":"Activation of thymic regeneration in mice and humans following androgen blockade","volume":"175","author":"Sutherland","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0505","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.exger.2009.03.003","article-title":"Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis","volume":"44","author":"Wang","year":"2009","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0510","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/pros.20906","article-title":"Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization","volume":"69","author":"Koh","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0515","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1158\/1078-0432.CCR-07-5048","article-title":"Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy","volume":"14","author":"Madan","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7S","key":"10.1016\/j.vaccine.2011.06.088_bib0520","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/jco.2011.29.7_suppl.163","article-title":"A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC) [abstract]","volume":"29","author":"Bilusic","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0525","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1078-0432.CCR-07-2056","article-title":"Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer","volume":"14","author":"Yokokawa","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0530","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1600-065X.2008.00605.x","article-title":"A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting","volume":"222","author":"Gray","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0535","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1158\/0008-5472.CAN-07-0445","article-title":"Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity","volume":"68","author":"Garcia-Hernandez","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0540","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/mi.10.4.2","article-title":"Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting","volume":"10","author":"Gray","year":"2010","journal-title":"Mol Interv"},{"issue":"Suppl. 6","key":"10.1016\/j.vaccine.2011.06.088_bib0545","doi-asserted-by":"crossref","first-page":"G52","DOI":"10.1016\/j.vaccine.2009.09.106","article-title":"Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages","volume":"27","author":"Gray","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0550","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1158\/1078-0432.CCR-04-1380","article-title":"Induction of an antigen cascade by diversified subcutaneous\/intratumoral vaccination is associated with antitumor responses","volume":"11","author":"Kudo-Saito","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0555","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1078-0432.CCR-03-0145","article-title":"Intratumoral vaccination and diversified subcutaneous\/intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules","volume":"10","author":"Kudo-Saito","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"7S","key":"10.1016\/j.vaccine.2011.06.088_bib0560","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/jco.2011.29.7_suppl.141","article-title":"Intraprostatic vaccine administration in patients with locally recurrent prostate cancer [abstract]","volume":"29","author":"Heery","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0565","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0090-4295(89)90248-3","article-title":"High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response","volume":"34","author":"Ferro","year":"1989","journal-title":"Urology"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0570","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3109\/07357909609076896","article-title":"Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer","volume":"14","author":"Figg","year":"1996","journal-title":"Cancer Invest"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0575","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.1998.16.5.1835","article-title":"Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer","volume":"16","author":"Smith","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0580","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.1993.11.4.607","article-title":"Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer","volume":"11","author":"Kelly","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0585","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/91.3.244","article-title":"Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer","volume":"91","author":"Scher","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0590","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1634\/theoncologist.2008-0016","article-title":"Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage","volume":"13","author":"Stein","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0595","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1634\/theoncologist.2008-0075","article-title":"Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data","volume":"13","author":"Stein","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0600","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","article-title":"Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0605","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2006.08.1935","article-title":"Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy","volume":"25","author":"Tang","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0610","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jnci\/djk091","article-title":"When you look matters: the effect of assessment schedule on progression-free survival","volume":"99","author":"Panageas","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0615","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2006.01.026","article-title":"RECIST revisited: a review of validation studies on tumour assessment","volume":"42","author":"Therasse","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0620","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1158\/1078-0432.CCR-07-0588","article-title":"Cancer vaccines: moving beyond current paradigms","volume":"13","author":"Schlom","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0625","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1634\/theoncologist.2010-0129","article-title":"Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression","volume":"15","author":"Madan","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0630","unstructured":"Hoos A. Proposal of a clinical development paradigm for cancer immunotherapy: novel endpoints. Presented at ASCO 2008 Annual Meeting, June 2, Chicago, IL. [June 2011]; Available from: http:\/\/www.asco.org\/ascov2\/MultiMedia\/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=55&sessionID=2624."},{"key":"10.1016\/j.vaccine.2011.06.088_bib0635","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/009286150704100412","article-title":"Consequences of delayed treatment effects on analysis of time-to-event endpoints","volume":"41","author":"Fine","year":"2007","journal-title":"Drug Inf J"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0640","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19970330)16:6<695::AID-SIM436>3.0.CO;2-C","article-title":"A partially grouped logrank test","volume":"16","author":"Sposto","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0645","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0650","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","article-title":"Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma","volume":"14","author":"Gulley","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0655","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1259\/bjr\/19323466","article-title":"Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes","volume":"77","author":"Jones","year":"2004","journal-title":"Br J Radiol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0660","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-05-1574","article-title":"Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma","volume":"12","author":"Loveland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0665","first-page":"1","article-title":"The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases","volume":"8","author":"Saenger","year":"2008","journal-title":"Cancer Immun"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0670","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0675","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0022-1759(88)90079-8","article-title":"Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells","volume":"110","author":"Czerkinsky","year":"1988","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0680","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/00365510500348252","article-title":"Inter-operator variation in ELISPOT analysis of measles virus-specific IFN-gamma-secreting T cells","volume":"65","author":"Ryan","year":"2005","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0685","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1089\/aid.2005.21.68","article-title":"Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials","volume":"21","author":"Cox","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0690","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1600-065X.2003.00092.x","article-title":"Immunologic monitoring","volume":"196","author":"Hernandez-Fuentes","year":"2003","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0695","first-page":"LB4517","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0700","doi-asserted-by":"crossref","first-page":"11810","DOI":"10.1073\/pnas.92.25.11810","article-title":"Human neoplasms elicit multiple specific immune responses in the autologous host","volume":"92","author":"Sahin","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0705","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09339","article-title":"Translating cancer research into targeted therapeutics","volume":"467","author":"de Bono","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0710","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1158\/1078-0432.CCR-08-1266","article-title":"Translational Research Working Group developmental pathway for immune response modifiers","volume":"14","author":"Cheever","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0715","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00262-007-0379-z","article-title":"Toward the harmonization of immune monitoring in clinical trials: quo vadis?","volume":"57","author":"Britten","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.cji.0000211341.88835.ae","article-title":"A clinical development paradigm for cancer vaccines and related biologics","volume":"30","author":"Hoos","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0725","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00262-007-0380-6","article-title":"Results and harmonization guidelines from two large-scale international ELISPOT proficiency panels conducted by the Cancer Vaccine Consortium (CVC\/SVI)","volume":"57","author":"Janetzki","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0730","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00262-009-0759-7","article-title":"Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations","volume":"59","author":"Boehm","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0735","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature10124","article-title":"A 2020 vision for vaccines against HIV, tuberculosis and malaria","volume":"473","author":"Rappuoli","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2011.06.088_bib0740","unstructured":"Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer. [April 2011]; Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01057810?term=NCT01057810&rank=1."},{"key":"10.1016\/j.vaccine.2011.06.088_bib0745","unstructured":"Study of Immunotherapy to Treat Advanced Prostate Cancer. [April 2011]; Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00861614?term=NCT00861614&rank=1."},{"key":"10.1016\/j.vaccine.2011.06.088_bib0750","unstructured":"Bavarian Nordic Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Trial of PROSTVAC\u00ae. Accessed: April 2011; Available from: http:\/\/www.bavarian-nordic.com\/investor\/announcements\/2010-40.aspx."},{"key":"10.1016\/j.vaccine.2011.06.088_bib0755","unstructured":"BioSante Pharmaceuticals: Cancer Vaccines. Accessed: March 2011; Available from: http:\/\/www.biosantepharma.com\/Cancer-Vaccines.php."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11009820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11009820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T21:06:53Z","timestamp":1560373613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11009820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":150,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0264410X11009820"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.06.088","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}